Full-Length Original Research
Adjunctive zonisamide therapy in the long-term treatment of children with partial epilepsy: Results of an open-label extension study of a phase III, randomized, double-blind, placebo-controlled trial
Article first published online: 22 FEB 2014
Wiley Periodicals, Inc. © 2014 International League Against Epilepsy
Volume 55, Issue 4, pages 568–578, April 2014
How to Cite
Epilepsia, 55(4):568–578, 2014
- Issue published online: 22 APR 2014
- Article first published online: 22 FEB 2014
- Manuscript Accepted: 3 JAN 2014
- Eisai Ltd
- Italian Ministry of Health
- European Community Sixth Framework Thematic Priority Life Sciences
- Genomics and Biotechnology for Health
- E-Rare EU
- Italian Ministry of Education
- University and Research
- Tuscany Region
- Pisa Foundation
- Telethon Foundation
- Mariani Foundation
|epi12548-sup-0002-FigS1.tif||image/tif||452K||Fig. S1. Study design.|
|epi12548-sup-0003-FigS2.tif||image/tif||1057K||Fig. S2. Responder rate (≥50% reduction in 28-day seizure frequency from Study 312 baseline) and seizure freedom rate (100% reduction in 28-day seizure frequency from Study 312 baseline) during the open-label period (safety population).|
Table S1. Patient demographics and baseline characteristics (safety population).
Table S2. (A) Tanner stages at baseline, study entry, and open-label visit 3 (weeks 40–43) and (B) transitions between Tanner stages (increases in one group) from baseline to study entry and open-label visit 3 (weeks 40–43; safety population).
Table S3. School Performance (safety population).
Table S4. Controlled Oral Word Association Test (patients with an intelligence quotient of at least 75; safety population).
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.